Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

everolimus

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

- PMLiVE

Novartis to invest $23bn into US-based infrastructure over next five years

The commitment will allow the company to produce 100% of its key medicines end-to-end in the US

- PMLiVE

Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy

Almost 13 out of every million people in the US are diagnosed with IgAN each year

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy

The company said it is planning to file regulatory applications for OAV101 IT this year

- PMLiVE

NICE recommends Pharming’s Joenja as first treatment for ultra-rare immune disease APDS

Approximately 40 to 50 people in the UK are known to be living with the inherited disorder

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links